Petri László, Gabizon Ronen, Ferenczy György G, Péczka Nikolett, Egyed Attila, Ábrányi-Balogh Péter, Takács Tamás, Keserű György M
Medicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, HUN-REN Research Centre for Natural Sciences, 2 Magyar tudósok krt, Budapest 1117, Hungary.
Department of Chemical and Structural Biology, Weizmann Institute of Science, Helen and Milton A. Kimmelman bldg, Rehovot 76100, Israel.
J Med Chem. 2025 Mar 27;68(6):6616-6632. doi: 10.1021/acs.jmedchem.5c00017. Epub 2025 Mar 18.
Labeling proteins with covalent ligands is finding increasing use in proteomics applications, including identifying nucleophilic residues amenable for labeling and in the development of targeted covalent inhibitors (TCIs). Labeling efficiency is measured by the covalent occupancy of the target or by biochemical activity. Here, we investigate how these observed quantities relate to the intrinsic parameters of complex formation, namely, noncovalent affinity and covalent reactivity, and to experimental conditions, including incubation time and ligand concentration. It is shown that target engagement is beneficially driven by noncovalent recognition for lead-like compounds, which are appropriate starting points for targeted covalent inhibitors owing to their easily detectable occupancy and fixed binding mode, facilitating optimization. In contrast, labeling by fragment-sized compounds is inevitably reactivity-driven as their small size limits noncovalent affinity. They are well-suited for exploring ligandable nucleophilic residues, while small fragments are less appropriate starting points for TCI development.
用共价配体标记蛋白质在蛋白质组学应用中越来越受到重视,包括识别适合标记的亲核残基以及开发靶向共价抑制剂(TCI)。标记效率通过靶标的共价占有率或生化活性来衡量。在这里,我们研究这些观察到的量如何与复合物形成的内在参数,即非共价亲和力和共价反应性,以及与实验条件,包括孵育时间和配体浓度相关。结果表明,对于类先导化合物,非共价识别有利于驱动靶标结合,由于其易于检测的占有率和固定的结合模式,类先导化合物是靶向共价抑制剂的合适起始点,便于优化。相比之下,片段大小的化合物标记不可避免地由反应性驱动,因为它们的小尺寸限制了非共价亲和力。它们非常适合于探索可配体的亲核残基,而小片段对于TCI开发来说不太适合作为起始点。